Drug trial targets rare genetic overgrowth disorder
NCT ID NCT02443818
Summary
This study tested whether the drug sirolimus could stop the progression of abnormal, excessive growth in specific body parts of people with a genetic condition called PIK3CA-related overgrowth. Sixteen participants, aged 3 to 65, took sirolimus for six months after a six-month monitoring period. The main goal was to see if the drug could reduce or halt the growth of the overgrown tissue, measured by MRI scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEGMENTAL OVERGROWTH DISORDERS DUE TO PIK3CA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Montpellier - Hôpital Saint-Eloi
Montpellier, 34295, France
-
CHRU de Tours
Tours, 37044, France
-
CHU Paris - Necker
Paris, 75015, France
-
CHU d'Angers
Angers, 49933, France
-
CHU de Bordeaux - GH Pellegrin
Bordeaux, 33076, France
-
CHU de DIJON
Dijon, 21079, France
-
HCL Lyon - CH Lyon Sud
Pierre-Bénite, 69495, France
-
Hopitaux de Brabois Chu Nancy
Nancy, 54511, France
-
Hôpital Jeanne de Flandre
Lille, 59037, France
-
Hôpital mère-enfant de Nantes
Nantes, 44093, France
-
Pôle Cardiovasculaire et Métabolique - Hôpital Larrey
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.